Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)

TP-020 (MGAT2-IN-1), MGAT2 Inhibitor

Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the

Diseases, Free Full-Text

NASH Drug Development: Seeing the Light at the End of the Tunnel?

Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the

MGAT2 inhibitor decreases liver fibrosis and inflammation in

Lipid metabolic flux analysis of compA in intestinal mucosa

US9701672B2 - Dihydropyridinone MGAT2 inhibitors for use in the

Metabolic dysfunction–associated fatty liver disease (MAFLD): an